This narrative review evaluates the potential of emerging biomarkers for early diagnosis and accurate prognosis in sepsis management, emphasizing their role in enhancing patient outcomes. Traditional biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) have limitations, while recent studies have identified novel biomarkers with increased sensitivity and specificity, including circular RNAs, HOXA distal transcript antisense RNA, microRNA-486-5p, protein C, triiodothyronine, and prokineticin 2. These biomarkers are crucial for early detection, prognostication, and guiding antibiotic therapy. Point-of-care testing technologies have revolutionized biomarker application, enabling swift and real-time patient evaluation. However, challenges such as biomarker variability and the lack of standardized thresholds persist. The review highlights the significance of multi-biomarker strategies and personalized medicine in sepsis management, advocating for large-scale verification and integration into clinical practice to maximize their efficacy in future sepsis treatment.This narrative review evaluates the potential of emerging biomarkers for early diagnosis and accurate prognosis in sepsis management, emphasizing their role in enhancing patient outcomes. Traditional biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) have limitations, while recent studies have identified novel biomarkers with increased sensitivity and specificity, including circular RNAs, HOXA distal transcript antisense RNA, microRNA-486-5p, protein C, triiodothyronine, and prokineticin 2. These biomarkers are crucial for early detection, prognostication, and guiding antibiotic therapy. Point-of-care testing technologies have revolutionized biomarker application, enabling swift and real-time patient evaluation. However, challenges such as biomarker variability and the lack of standardized thresholds persist. The review highlights the significance of multi-biomarker strategies and personalized medicine in sepsis management, advocating for large-scale verification and integration into clinical practice to maximize their efficacy in future sepsis treatment.